In addition, in vitro experiments revealed that blocking YTHDF1 improved the therapeutic effect of anti-PD-L1 in GC cells, and the knockout of m6A demethylase AlKBH5 makes tumor sensitive to anti PD-1 immunotherapy and changes immune cell recruitment (167, 169). Here, ALKBH5 is linked to neoplasm.